{
    "clinical_study": {
        "@rank": "127861", 
        "arm_group": [
            {
                "arm_group_label": "Dulera adherence monitoring", 
                "arm_group_type": "Experimental", 
                "description": "Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence"
            }, 
            {
                "arm_group_label": "Dulera Standard of Asthma Care", 
                "arm_group_type": "Active Comparator", 
                "description": "Dulera standard of asthma care"
            }
        ], 
        "brief_summary": {
            "textblock": "40 subjects with moderate-to-severe asthma will be randomly selected for study in which 20,\n      will be monitored for medication use (Dulera 100/5, Dulera 200/5 and Proventil HFA) over 3\n      months. These intervention subjects will receive medication use feedback at each visit,\n      while the control group will receive the standard of asthma care. Those interventional\n      subjects with Dulera adherence<60% will receive feedback based on an asthma adherence\n      disease management model protocol, Asthma Adherence Pathway. Intervention clinicians will\n      been trained in Motivational Interviewing to reduce subject ambivalence about medication\n      use. The primary hypothesis is that subjects who receive medication monitoring and\n      Motivational Interviewing adherence strategies will have better asthma control, as measured\n      by the Asthma Control Questionnaire, than the control group."
        }, 
        "brief_title": "Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "Primary Clinical Hypothesis: Poorly controlled subjects with moderate-to-severe asthma\n      (measured by Asthma Control Questionnaire (ACQ) \u2265 1) despite treatment with Dulera, who are\n      treated with the asthma adherence disease management protocol, Asthma Adherence Pathway\u2122,\n      will achieve greater asthma control than similar control subjects who are treated with the\n      current standard of care.\n\n      Primary end point: There will be four measures of Asthma Control Questionnaire (ACQ) over\n      time over 3 months. The primary endpoint is the third month measure of ACQ.\n\n      Secondary Clinical Hypothesis: The asthma adherence disease management program, Asthma\n      Adherence Pathway\u2122, will increase observed adherence to Dulera relative to a benchmark of\n      60% adherence (i.e., expected prescribed actuations).\n\n      Secondary end points: a) Average adherence to Dulera over the three month study period\n\n      Tertiary Clinical Hypothesis: Responses to Adult Asthma Adherence Questionnaire (AAAQ) will\n      be related to Dulera Adherence\n\n      Tertiary Study Endpoints: There will be 2 measures of the AAAQ (first and last visit) and\n      the tertiary endpoint is the last visit"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Physician diagnosis of asthma of moderate severity\n\n          2. Subjects \u2265 18 years of age\n\n          3. Currently receiving an inhaled corticosteroid medication and being prescribed Dulera\n             100/5 as part of standard of care based upon asthma severity and dosing guidelines\n\n          4. Asthma Control Questionnaire (ACQ) result > 1.0 at entry\n\n          5. Demonstration of correct inhalation technique for use of meter-dosed inhalers (MDIs)\n\n          6. History of reversible airway obstruction documented by treating physician Exclusion\n             Criteria: intermittent asthma; emphysema, chronic obstructive pulmonary disease;\n             chronic bronchitis; cystic fibrosis; medication that may have a drug interaction with\n             Dulera\n\n        Exclusion Criteria\n\n          1. Intermittent asthma (asthma exacerbations or symptoms < 3 days/week)\n\n          2. Diagnosis of emphysema in prior year\n\n          3. Diagnosis at any time of: chronic obstructive pulmonary disease (COPD), chronic\n             bronchitis, cystic fibrosis, bronchiectasis, Churg Strauss, Wegener's, sarcoidosis,\n             pulmonary hypertension or lung cancer\n\n          4. On any medication documented to have a drug interaction with Dulera"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02045875", 
            "org_study_id": "RC-5816"
        }, 
        "intervention": {
            "arm_group_label": [
                "Dulera adherence monitoring", 
                "Dulera Standard of Asthma Care"
            ], 
            "description": "Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.", 
            "intervention_name": "Dulera", 
            "intervention_type": "Drug", 
            "other_name": "mometasone furoate/formoterol fumarate dihydrate"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Formoterol", 
                "Mometasone furoate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Adherence monitoring", 
            "Motivational Interviewing Adherence strategies"
        ], 
        "lastchanged_date": "January 23, 2014", 
        "location": {
            "contact": {
                "email": "dgentile@wpahs.org", 
                "last_name": "Deborah Gentile, MD", 
                "phone": "412-359-4490"
            }, 
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15212"
                }, 
                "name": "West Penn Allegheny Health System"
            }, 
            "investigator": {
                "last_name": "Deborah Gentile, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence", 
        "other_outcome": {
            "description": "The AAAQ was developed measuring prescription re-fill and subject responses. (JACI: In practice 2013;1:55). The 20 patients who receive the AAAQ, will be part of a larger patient cohort from multiple studies in the future, who will also undergo medication monitoring with daily anti-inflammatory treatment", 
            "measure": "Validation of an adult asthma adherence questionnaire (AAAQ)", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "overall_contact": {
            "email": "Dgentile@wpahs.org", 
            "last_name": "Deborah Gentile, DO", 
            "phone": "412 359 6654"
        }, 
        "overall_contact_backup": {
            "email": "dskoner@wpahs.org", 
            "last_name": "David Skoner, MD", 
            "phone": "412 359 6654"
        }, 
        "overall_official": {
            "affiliation": "West Penn Allegheny Health System", 
            "last_name": "Deborah Gentile, DO", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Asthma Control Questionnaire measured at each office visit", 
            "measure": "Asthma Control", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02045875"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Subjects in the monitoring group will have adherence greater than or equal to the 60% benchmark", 
            "measure": "Adherence to Dulera 100/5 and 200/5", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "source": "Asthma Management Systems", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Merck Sharp & Dohme Corp.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "West Penn Allegheny Health System", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Asthma Management Systems", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}